JUMPCAN(SH:600566) Changjiang Securities·2025-06-22 04:54Investment Rating - The report initiates coverage with a "Buy" rating for the company [10][11]. Core Insights - The company focuses on the production and sales of pediatric, respiratory, digestive, gynecological, and other pharmaceutical products, with key products including Pudilan Anti-inflammatory Oral Liquid and Pediatric Chiqiao Qingre Granules. The company is also advancing its industrial transformation and upgrading, continuously introducing high-quality BD products since 2021 to empower external expansion and lay a foundation for long-term development [3][7]. Revenue and Profitability - The company's revenue grew from 7.208 billion to 9.655 billion from 2018 to 2023, with a CAGR of 6.02%. The net profit attributable to the parent company increased from 1.688 billion to 2.823 billion during the same period, with a CAGR of 10.83%. In 2024, the company expects revenue of 8.017 billion, a year-on-year decline of 16.96%, and a net profit of 2.532 billion, down 10.32% year-on-year [27][28]. Product Matrix - The company’s core products, Pudilan Anti-inflammatory Oral Liquid and Pediatric Chiqiao Qingre Granules, account for over 75% of total revenue, ensuring stable income. Secondary products include Protein Succinyl Iron Oral Solution, Digestive Health Oral Solution, and Huanglong Cough Granules, which are expected to contribute additional revenue in the medium to long term [8][32]. BD Strategy - Since 2022, the company has implemented stock incentive plans and aims to introduce at least four BD products annually, continuously expanding its new drug pipeline. The first batch of products includes long-acting anti-influenza drugs, oral psoriasis medications, and long-acting growth hormones, which are expected to provide sustained growth momentum [9][38]. Key Product Performance - Pudilan Anti-inflammatory Oral Liquid has become a top product in the market despite exiting provincial medical insurance lists, thanks to retail market expansion and unique dosage forms. Pediatric Chiqiao Qingre Granules, a newly developed syrup form, has also been successfully included in medical insurance, contributing to revenue recovery [43][51]. Financial Forecast - The company forecasts revenues of 7.578 billion, 8.074 billion, and 8.707 billion for 2025-2027, with net profits of 2.257 billion, 2.494 billion, and 2.733 billion respectively, corresponding to EPS of 2.45, 2.71, and 2.97 [10].